Electrochemiluminescence Mechanisms Investigated with Smartphone-Based Sensor Data Modeling, Parameter Estimation and Sensitivity Analysis

The present study introduces a unified framework combining a mechanistic model with a genetic algorithm (GA) for the parameter estimation of electrochemiluminescence (ECL) kinetics of the Ru(bpy)32+/TPrA system occurring in a smartphone‐based sensor. The framework allows a straightforward solution for simultaneous estimation of multiple parameters which can be, otherwise, time‐consuming and lead to non‐convergence. Model parameters are estimated by achieving a high correlation between the model prediction and the measured ECL intensity from the ECL sensor. The developed model is used to perform a sensitivity analysis (SA), which provides quantitative effects of the model parameters on the concentrations of chemical species involved in the system. The results demonstrate that the GA‐based parameter estimation and the SA approaches are effective in analyzing the kinetics of the ECL mechanism. Therefore, these approaches can be incorporated as analysis tools in the ECL kinetics study with practical application in the calibration of mechanistic models for any required sensing condition

Parameter estimation for VLE calculation by global minimization: the genetic algorithm

Vapor-liquid equilibrium calculations require global minimization of deviations in pressure and gas phase compositions. In this work, two versions of a stochastic global optimization technique, the genetic algorithm, the freeware MyGA program, and the modified mMyGA program, are evaluated and compared for vapor-liquid equilibrium problems. Reliable experimental data from the literature on vapor liquid equilibrium for water + formic acid, tert-butanol + 1-butanol and water + 1,2-ethanediol systems were correlated using the Wilson equation for activity coefficients, considering acid association in both liquid and vapor phases. The results show that the modified mMyGA is generally more accurate and reliable than the original MyGA. Next, the mMyGA program is applied to the CO2 + ethanol and CO2 + 1-n-butyl-3-methylimidazolium hexafluorophosphate systems, and the results show a good fit for the data

Rivaroxaban with or without aspirin in stable cardiovascular disease

BACKGROUND: We evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention. METHODS: In this double-blind trial, we randomly assigned 27,395 participants with stable atherosclerotic vascular disease to receive rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily), rivaroxaban (5 mg twice daily), or aspirin (100 mg once daily). The primary outcome was a composite of cardiovascular death, stroke, or myocardial infarction. The study was stopped for superiority of the rivaroxaban-plus-aspirin group after a mean follow-up of 23 months. RESULTS: The primary outcome occurred in fewer patients in the rivaroxaban-plus-aspirin group than in the aspirin-alone group (379 patients [4.1%] vs. 496 patients [5.4%]; hazard ratio, 0.76; 95% confidence interval [CI], 0.66 to 0.86; P<0.001; z=−4.126), but major bleeding events occurred in more patients in the rivaroxaban-plus-aspirin group (288 patients [3.1%] vs. 170 patients [1.9%]; hazard ratio, 1.70; 95% CI, 1.40 to 2.05; P<0.001). There was no significant difference in intracranial or fatal bleeding between these two groups. There were 313 deaths (3.4%) in the rivaroxaban-plus-aspirin group as compared with 378 (4.1%) in the aspirin-alone group (hazard ratio, 0.82; 95% CI, 0.71 to 0.96; P=0.01; threshold P value for significance, 0.0025). The primary outcome did not occur in significantly fewer patients in the rivaroxaban-alone group than in the aspirin-alone group, but major bleeding events occurred in more patients in the rivaroxaban-alone group. CONCLUSIONS: Among patients with stable atherosclerotic vascular disease, those assigned to rivaroxaban (2.5 mg twice daily) plus aspirin had better cardiovascular outcomes and more major bleeding events than those assigned to aspirin alone. Rivaroxaban (5 mg twice daily) alone did not result in better cardiovascular outcomes than aspirin alone and resulted in more major bleeding events